3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
1279
Carcinoma, Non-Small-Cell Lung
927
Prostatic Neoplasms
729
Neoplasms
633
Multiple Myeloma
554
Lymphoma
540
Colorectal Neoplasms
530
Lung Neoplasms
515
Leukemia
498
Leukemia, Myeloid, Acute
474
Neoplasm Metastasis
471
Melanoma
426
Lymphoma, Non-Hodgkin
420
Ovarian Neoplasms
418
Leukemia, Lymphocytic, Chronic, B-Cell
386
Pancreatic Neoplasms
373
Recurrence
340
Precursor Cell Lymphoblastic Leukemia-Lymphoma
329
Head and Neck Neoplasms
307
Lymphoma, Large B-Cell, Diffuse
296
Glioblastoma
294
Myelodysplastic Syndromes
288
Lymphoma, Follicular
287
Brain Neoplasms
287
Stomach Neoplasms
283
Carcinoma, Renal Cell
268
Carcinoma, Hepatocellular
262
Hodgkin Disease
261
Rectal Neoplasms
256
Sarcoma
251
Interventions
abemaciclib
1
Trastuzumab
1
Fulvestrant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Completed
×
Hormone Receptor Positive Breast Cancer
×
Clear all
NCT02675231
2024-11-26
monarcHER
Eli Lilly and Company
Phase 2
Completed
237 enrolled
25 charts